Aller au contenu

Publications scientifiques

  • article Laprise JF, Chesson HW, Markowitz LE, Drolet M, Brisson M

    Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the Uni…

    Ann Intern Med 178 (1), 2025.

  • article Middeldorp M, Donken R, Nirmal A, Smith B, Citlali Marquez A, Bettinger JA, Brisson M, Burchell AN, Dobson SR, Dawar M, Franco EL, Grennan T, Krajden M, Mayrand MH, McNeil S, Naus M, Sauvageau C, Singer J, Smith LW, Ogilvie GS, Sadarangani M

    Quadrivalent HPV Vaccine Evaluation Study with Addition of the Nonavalent Vaccine (QUEST-ADVANCE): protocol of an observational cohort study

    BMJ Open 15 (9), 2025.

  • article Laprise JF, Chesson HW, Markowitz LE, Drolet M, Brisson M

    Cost-Effectiveness of Extending Human Papillomavirus Vaccination to Population Subgroups Older Than 26 Years Who Are at Higher Risk for Human Papillomavirus Infection in the Unit…

    Ann Intern Med 178 (11), 2025.

  • article Bénard É and Drolet M, Gingras G, Laprise JF, Sabourin AA, Bloem P, Akaba H, Brotherton J, Jit M, Brisson M

    Ranking the most efficient human papillomavirus vaccination strategies in low-income and lower-middle income countries: a mathematical modelling analysis

    Lancet Glob Health 13 (12), 2025.

  • article Wright J, Crowcroft N, McLachlan E, Perez-Iratxeta C, Joh E, Osman S, Hatchette T, Deeks SL, Wilson SE, Hughes SL, Halperin SA, Buchan SA, Ward BJ, Gubbay J, Brisson M, Serhir B, Severini A, Bolotin S

    Population immunity to varicella in Canada: A Canadian Immunization Research Network (CIRN) study

    PLoS One 19 (8), 2024.

  • article Prem K, Cernuschi T, Malvolti S, Brisson M, Jit M

    Optimal human papillomavirus vaccination strategies in the context of vaccine supply constraints in 100 countries

    EClinicalMedicine 74 2024.

  • article Whitworth HS, Mounier-Jack S, Choi EM, Gallagher KE, Howard N, Kelly H, Mbwanji G, Kreimer AR, Basu P, Barnabas R, Drolet M, Brisson M, Watson-Jones D

    Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of eviden…

    Vaccine X 19 2024.

  • article Burger EA, Laprise JF, Portnoy A, Spencer JC, Sy S, Regan MC, Bénard É and Drolet M, Brisson M, Kim JJ

    Population-level health impact of hypothetical waning 1-dose human papillomavirus vaccination and 2-dose mitigation strategies in a high cervical cancer burden setting

    J Natl Cancer Inst Monogr 2024 (67), 2024.

  • article Brisson M, Laprise JF, Drolet M, Chamberland É and Bénard É and Burger EA, Jit M, Kim JJ, Markowitz LE, Sauvageau C, Sy S

    Population-level impact of switching to 1-dose human papillomavirus vaccination in high-income countries: examining uncertainties using mathematical modeling

    J Natl Cancer Inst Monogr 2024 (67), 2024.

  • article Drolet M, Laprise JF, Chamberland É and Sauvageau C, Wilson S, Lim GH, Ogilvie G, Tuite A, Brisson M

    Switching from a 2-dose to a 1-dose program of gender-neutral routine vaccination against human papillomavirus in Canada: a mathematical modelling analysis

    CMAJ 196 (33), 2024.

  • article Yokoji K, Giguère K, Malagón T, Rönn MM, Mayaud P, Kelly H, Delany-Moretlwe S, Drolet M, Brisson M, Boily MC, Maheu-Giroux M

    Association of naturally acquired type-specific HPV antibodies and subsequent HPV re-detection: systematic review and meta-analysis

    Infect Agent Cancer 18 (1), 2023.

  • article Anato JLF, Ma H, Hamilton MA, Xia Y, Harper S, Buckeridge D, Brisson M, Hillmer MP, Malikov K, Kerem A, Beall R, Wagner CE, Racine É and Baral S, Dubé È and Mishra S, Maheu-Giroux M

    Impact of a vaccine passport on first-dose SARS-CoV-2 vaccine coverage by age and area-level social determinants of health in the Canadian provinces of Quebec and Ontario: an in…

    CMAJ Open 11 (5), 2023.